Eli Lilly And Company Disclose Form 10-K Including Orforglipron Related Information
21/02/2024 23:35
Feb 22 (Reuters) - Chugai Pharmaceutical Co Ltd
4519.T :
* CHUGAI PHARMACEUTICAL CO LTD- ELI LILLY AND COMPANY
DISCLOSES
FORM 10-K INCLUDING ORFORGLIPRON RELATED INFORMATION
* CHUGAI PHARMACEUTICAL CO LTD- COMPANY IS ELIGIBLE TO
RECEIVE UP
TO $140 MLN CONTINGENT UPON ACHIEVEMENT OF SUCCESS-BASED
REGULATORY MILESTONES AND UP TO $250 MLN IN A SERIES OF
SALES-BASED MILESTONES, CONTINGENT UPON COMMERCIAL SUCCESS OF
ORFORGLIPRON
Source text for Eikon: ID:nTSnu841c0
Further company coverage: 4519.T
(Reporting by Rocky Swift)
((rocky.swift@thomsonreuters.com;))
Recent news on Chugai Pharmaceutical
See all newsRegarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Table: Chugai Pharm 6-MTH group results (IFRS)
Japan's Nikkei roars past 62,000 on earnings, Middle East optimism; JGBs rally (updated)
Japan's Nikkei surges past 61,000 for first time on earnings, Mideast optimism
Japan's Nikkei closes above 60,000 for first time on earnings optimism (updated)